The role of orexin in fatigue and sleep quality in patients with primary Sjögren’s syndrome; [Die Rolle von Orexin bei Fatigue und Schlafqualität bei Patienten mit primärem Sjögren-Syndrom]

被引:0
作者
Sandikci S.C. [1 ]
Gultuna S. [2 ]
Ozisler C. [1 ]
Aydin F.N. [3 ]
机构
[1] Department of Rheumatology, Ankara Etlik City Hospital, Ankara
[2] Department of Immunology and Allergy, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara
[3] Department of Biochemistry, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara
关键词
Disease activity; Fatigue; Orexin; Sjögren’s syndrome; Sleepiness;
D O I
10.1007/s00393-023-01462-y
中图分类号
学科分类号
摘要
Background: Sleep disorders and fatigue are prevalent symptoms affecting primary Sjögren’s syndrome (pSS) patients. This study aimed to assess the sleep quality of pSS patients as well as its relationship to fatigue and orexin level. Methods: This is a cross-sectional study evaluating fatigue in pSS using the Fatigue Severity Scale (FSS). Sleep quality was evaluated using the Pittsburg Sleep Quality Index (PSQI). The European Alliance of Associations for Rheumatology (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI) and EULAR Sjögren’s Syndrome Patient-Reported Index (ESSPRI) were calculated. Results: Forty-one patients met the sample criteria and were involved in the final report. They were all females, with a mean (± SD) age and median disease duration of 40.87 ± 10.84 and 36 (6–180) months, respectively. The mean ESSDAI was 0.92 ± 1.3, while the mean ESSPRI was 5.8 ± 2.13. Based on the FSS, 32 (78.04%) patients had a positive test with a mean score of 5.07 ± 1.54. The total PSQI score showed that 60.97% had poor sleep, and the orexin level was lower in patients with pSS than in healthy controls. There was no correlation between orexin level and the presence of fatigue nor the PSQI score. Conclusion: In conclusion, serum orexin levels were lower in patients with pSS than healthy controls, It could be related to impairments in sleep and fatigue in patients with pSS. © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2023.
引用
收藏
页码:242 / 247
页数:5
相关论文
共 27 条
[1]  
Ambrosio L.M., Rovai E.S., Franca B.N., Et al., Effects of periodontal treatment on primary sjogren’s syndrome symptoms, Braz oral res, 31, (2017)
[2]  
Mavragani C.P., Moutsopoulos H.M., Sjögren syndrome, Cmaj, 186, pp. E579-E586, (2014)
[3]  
Theander L., Strombeck B., Mandl T., Theander E., Sleepiness or fatigue? Can we detect treatable causes of tiredness in primary sjogren’s syndrome?, Rheumatol (Oxford), 49, pp. 1177-1183, (2010)
[4]  
Alain C., Thierry V., Pascal N., Valerie G., Catalina A., Yossan-VT, Orexins as novel therapeutic targets in inflammatory and neurodegenerative diseases, Front Endocrinol (Lausanne), 10, (2019)
[5]  
Seror R., Ravaud P., Mariette X., Et al., EULAR Sjögren’s syndrome patient reported index (ESSPRI): development of a consensus patient index for primary sjögren’s syndrome, Ann Rheum Dis, 70, pp. 968-972, (2011)
[6]  
Seror R., Theander E., Brun J.G., Et al., Validation of EULAR primary sjogren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI), Ann Rheum Dis, 74, pp. 859-866, (2015)
[7]  
Bertolazi A.N., Fagondes S.C., Hoff L.S., Dartora E.G., Miozzo I.C., de Barba M.E., Barreto S.S., Validation of the Brazilian Portuguese version of the Pittsburgh sleep quality index, Sleep Med, 12, pp. 70-75, (2011)
[8]  
Dong-Sheng S., Shao-Kun X., Lin W., Li Z., Hai-Yan Y., Juan-Qin S., The weighted combination of the epworth sleepiness scale and the STOP-bang questionnaire improved the predictive value of for OSAHS in hypertensive patients, Int J Gen Med, 15, pp. 6909-6915, (2022)
[9]  
Karolina C.W., Pawel R., Malgorzata W., Ilona P., Maciej W., Health-related quality of life (Nottingham health profile) in patients with endometriomas: correlation with clinical variables and self-reported limitations, Arch Med Sci, 16, pp. 584-591, (2019)
[10]  
Krupp L.B., Larocca N.G., Muir-Nash J., Steinberg A.D., The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus, Arch Neurol, 46, pp. 1121-1123, (1989)